Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of subjects treated with gene-modified T cells
NL-OMON61007Phase 3Recruiting
- Sponsor
- Celgene Corporation
- Start
- Jan 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of BMS-986453 in cancer, sponsored by Celgene Corporation. Started Jan 2021; status: recruiting.
02
Drugs
BMS-986453
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON61007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61007.